Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

CITY-FXI

Oligonucleotide (siRNA) · Gene silencing: Coagulation factor XI (F11) · developed by City Therapeutics

Phase 1 Most advanced trial
CTY Developer
1 Registered trials

What is CITY-FXI?

CITY-FXI is a small interfering RNA (siRNA) given by subcutaneous injection.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Oligonucleotide (siRNA)
Targets
Coagulation factor XI (F11)
Mechanism
Gene silencing: Coagulation factor XI (F11)
Therapy area
Cardiovascular
Developer
City Therapeutics (CTY)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07430397 Phase 1 Factor V Leiden Recruiting CTY

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Factor V LeidenProthrombin G20210AVenous Thromboembolism (VTE)

Other drugs acting on F11

More from City Therapeutics

Sources

Updated Oct 25, 2026. Something wrong or missing? Report it on the CTY page.

Follow CTY, the company behind CITY-FXI

See CTY's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

CTY catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.